Compositions for targeting conducting airway cells comprising adeno-associated virus constructs
View Patent ↗An artificial AAV capsid comprising a heterologous conducting airway targeting sequence is provided. The artificial AAV is useful as a targeting moiety, for delivery of heterologous molecules which are associated therewith. The artificial AAV is also useful in the generation of AAV vectors having the artificial capsid. Also described are methods of modifying the native tropism and transduction efficiency of vectors by improving and/or ablating their ability to transduce conducting airway cells. Methods of targeting conducting airway cells and delivering therapeutic and other molecules thereto are also provided.
1. An adeno-associated virus (AAV) vector useful for targeting conducting airway cells, wherein the vector has an AAV capsid and an expression cassette packaged therein, wherein the capsid comprises a chimeric capsid protein comprising an airway conducting cell targeting peptide and at least amino acids (aa) 1 to aa 389 and aa 524 to aa 736 of an AAV9 capsid protein having the amino acid sequence of SEQ ID NO: 2, wherein the airway conducting cell targeting peptide comprises one of (a) to (d):
(a) aa 447 to aa 521 of the amino acid sequence of SEQ ID NO:1;
(b) aa 450 to aa 469 of the amino acid sequence of SEQ ID NO:1 and aa 487 to aa 505 of the amino acid sequence of SEQ ID NO:1;
(c) aa 487 to aa 505 of the amino acid sequence of SEQ ID NO:1; or
(d) aa 447 to aa 469 of the amino acid sequence of SEQ ID NO:1;
wherein the airway conducting cell targeting peptide is located in the chimeric capsid protein in a location corresponding to the location of the targeting peptide in the AAV6 capsid protein, wherein the corresponding location of the airway conducting cell targeting peptide location is determined by a sequence alignment between the chimeric capsid protein and the AAV9 capsid protein, and wherein the expression cassette comprises at least one AAV inverted terminal repeat sequence and a heterologous gene operably linked to regulatory sequences which permit expression of the heterologous gene in the conducting airway cells.
2. The AAV vector according to claim 1 , wherein the airway conducting cell targeting peptide has the amino acid sequence of SEQ ID NO: 4: NRTQNQSGSAQNKDLLFSRGSPAGMSVQPKNWLPGPCYRQQRVSKTKTDNNNSNFTW TGASKYNLNGRESIINPG.
3. The AAV vector according to claim 1 , wherein the heterologous gene encodes a product useful for treating or ameliorating the symptoms of cystic fibrosis.
4. The AAV vector according to claim 1 , where the heterologous gene encodes a product selected from the group consisting of a functional cystic fibrosis transmembrane regulator (CFTR), an alpha-1 antitrypsin (A1AT), a surfactant protein C (SPC), and a surfactant protein D (SPD).
5. A composition comprising the AAV vector according to claim 1 and a physiologically compatible carrier.
6. An adeno-associated virus (AAV) vector useful for targeting conducting airway cells, wherein the vector has an AAV capsid and an expression cassette packaged therein, wherein the AAV capsid comprises a chimeric capsid protein comprising at least variable loop regions III and VI of a non-Clade-A capsid protein and an airway conducting cell targeting peptide, wherein the variable loop region III of the non-Clade-A capsid protein corresponds to amino acid (aa) 381 to aa 388 of an AAV6 capsid protein having the amino acid sequence of SEQ ID NO: 1 and the variable loop region VI corresponds to amino acids from aa 524 to 541 of the amino acid sequence of SEQ ID NO: 1, wherein the airway conducting cell targeting peptide comprises one of (a) to (d):
(a) aa 447 to aa 521 of the amino acid sequence of SEQ ID NO:1;
(b) aa 450 to aa 469 of the amino acid sequence of SEQ ID NO:1 and aa 487 to aa 505 of the amino acid sequence of SEQ ID NO:1;
(c) aa 487 to aa 505 of the amino acid sequence of SEQ ID NO:1; or
(d) aa 447 to aa 469 of the amino acid sequence of SEQ ID NO:1;
wherein the airway conducting cell targeting peptide is located in the chimeric capsid protein in a location corresponding to the location of the targeting peptide in the AAV6 capsid protein, wherein the corresponding location of the airway conducting cell targeting peptide location is determined by a sequence alignment between the chimeric capsid protein and the AAV9 capsid protein, and wherein said expression cassette comprises at least one AAV inverted terminal repeat sequence and a heterologous gene operably linked to regulatory sequences which permit expression of the heterologous gene in the conducting airway cells.
7. The AAV vector according to claim 6 , wherein the airway conducting cell targeting peptide has the amino acid sequence of SEQ ID NO: 4: NRTQNQSGSAQNKDLLFSRGSPAGMSVQPKNWLPGPCYRQQRVSKTKTDNNNSNFTW TGASKYNLNGRESIINPG.
8. The AAV vector according to claim 6 , wherein the heterologous gene encodes a product useful for treating or ameliorating the symptoms of cystic fibrosis.
9. The AAV vector according to claim 6 , wherein the heterologous gene encodes a product selected from the group consisting of a functional cystic fibrosis transmembrane regulator (CFTR), an alpha-1 antitrypsin (A1AT), a surfactant protein C (SPC), and a surfactant protein D (SPD).
10. A pharmaceutical composition comprising the AAV vector according to claim 6 and a physiologically compatible carrier.
11. The composition according to claim 10 , which is formulated for intranasal, oral or intratracheal delivery.
12. The AAV vector according to claim 6 , wherein the airway conducting cell targeting peptide comprises aa 450 to aa 469 of the amino acid sequence of SEQ ID NO:1 and aa 487 to aa 505 of the amino acid sequence of SEQ ID NO:1.
13. The AAV vector according to claim 6 , wherein the airway conducting cell targeting peptide comprises aa 487 to aa 505 of the amino acid sequence of SEQ ID NO:1.
14. The AAV vector according to claim 6 , wherein the airway conducting cell targeting peptide comprises aa 447 to aa 469 of the amino acid sequence of SEQ ID NO:1.